IP Library › Granted Patent US 9,040,518
Granted Patent B2
US 9,040,518 · App. 13/640,166 · Granted May 26, 2015

Chemical compounds

Inventors: Christopher Joseph Aquino (Research Triangle Park, NC); Jon Loren Collins (Research Triangle Park, NC); David John Cowan (Research Triangle Park, NC); Yulin Wu (Research Triangle Park, NC)
Assignee: GlaxoSmithKline LLC
C07D281/10C07D417/06C07F9/6541
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,040,518
App. No.
13/640,166
Granted
May 26, 2015
Kind
B2
Abstract

Compounds of Formula I and methods for treating metabolic disorders are disclosed.

Claims (30)

1. A compound of Formula I

wherein R 1 is H, Cl, Br, N(CH 3 ) 2 , or methoxy;

R 2 is H or OH;

each R 3 is independently C 1-6 alkyl;

X is CH 2 , C(O), or CH═CH;

Q is C 0-6 alkyl;

R 4 is OH, SO 3 H, CO 2 H, PO 3 H 2 , CONR 5 R 5 , NR 5 R 5 ; or NHC(O)CH 2 NR 5 R 5 ;

each R 5 is independently H, OH, C 1-6 alkyl, C 0-6 alkylCO 2 H, C 0-6 alkylSO 3 H, C 0-6 alkylPO 3 H 2 , C(O)C 0-6 alkylCO 2 H, C(O)C 0-6 alkylSO 3 H, C(O)C 0-6 alkylPO 3 H 2 , or CH(R 7 )C 0-6 alkyCO 2 H; and

R 7 is C 0-6 alkylCO 2 H, C 0-6 alkylOH, C 0-6 alkylSO 3 H, or C 0-6 alkylPO 3 H 2 .

2. A compound according to claim 1 wherein R 1 is methoxy.

3. A compound according to claim 2 wherein R 2 is H.

4. A compound according to claim 3 wherein X is CH 2 .

5. A compound according to claim 1 wherein X is C(O).

6. A compound according to claim 1 wherein Q is C 0-2 alkyl.

7. A compound according to claim 4 wherein Q is absent.

8. A compound according to claim 7 wherein each R 3 is independently C 2-4 alkyl.

9. A compound according to claim 8 wherein each R 3 is independently ethyl or n-butyl.

10. A compound according to claim 1 wherein R 4 is PO 3 H 2 .

11. A compound according to claim 9 wherein R 4 is NR 5 R 5 .

12. A compound according to claim 11 wherein one R 5 is H and the other is OH, methyl, C 1-4 alkylCO 2 H, C 0-2 alkylSO 3 H, C 1-2 alkylPO 3 H 2 , C(O)CO 2 H, C(O)C 1-2 alkylSO 3 H, C(O)C 1-2 alkylPO 3 H 2 , or CH(R 7 )C 0-1 alkyCO 2 H.

13. A compound according to claim 12 wherein one R 5 is H and the other is CH 2 CO 2 H, CH 2 SO 3 H, CH 2 CH 2 SO 3 H, or CH(R 7 )C 0-1 alkyCO 2 H.

14. A compound according to claim 13 wherein R 7 is C 0-1 alkylCO 2 H or C 0-2 alkylSO 3 H.

15. The compound

16. The compound

17. The compound of claim 16 wherein said compound is crystalline.

18. A pharmaceutically acceptable salt of a compound according to claim 1 .

19. A pharmaceutical composition comprising a compound according to claim 16 .

20. A method for treating diabetes mellitus (Type I or Type II) or obesity, in a human comprising administration of a composition according to claim 19 .

21. The method of claim 20 wherein said method is for treating Type II diabetes mellitus.

22. The method of claim 21 wherein said method further comprises administration of metformin.

Continuity (3)
Provisional Application 61328212 · Apr 27, 2010
Provisional Application 61329225 · Apr 29, 2010
Related Publication 20130029938A1 · Jan 31, 2013